Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey.

Barriers Clinicians Current practice Exercise Facilitators Lung cancer Oncologist Physical activity Recommendation

Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
07 2022
Historique:
received: 24 01 2022
revised: 12 05 2022
accepted: 16 05 2022
pubmed: 13 6 2022
medline: 22 6 2022
entrez: 12 6 2022
Statut: ppublish

Résumé

Exercise has been reported to alleviate disease as well as treatment impact in patients with lung cancer. Nevertheless, there is limited information available regarding the perception of lung cancer dedicated healthcare professionals' and their advice on exercise. An online survey exploring healthcare professionals' practice patterns, perceptions, barriers, and facilitators of exercise in patients with lung cancer was conducted within members of the EORTC Lung Cancer Group (LCG). One hundred forty-one healthcare providers completed the survey, mainly medical and radiation oncologists. Overall, 63% of the study participants declared that they frequently assessed exercise level in their patients, and 43% of them reinforced the importance of exercise. However, only 10% referred patients to an exercise program or specialist. Although the majority of the respondents had a positive perception regarding the benefits and safety of exercise (even in patients with advanced disease and/or bone metastasis), two-thirds of clinicians reported not having adequate training about exercise counselling. Moreover, 53% reported to lack of knowledge of guidelines referring to exercise in patients with cancer. Several obstacles and facilitators to improve exercise promotion in lung cancer care were identified. Healthcare providers recognize the relevance and feasibility of exercise as part of cancer treatment intervention, but specific pathways to do the referral are frequently missing. Future structured and well-designed strategies and initiatives are needed to support an effective referral in order to implement exercise interventions routinely in clinical practice.

Identifiants

pubmed: 35691097
pii: S0169-5002(22)00439-1
doi: 10.1016/j.lungcan.2022.05.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-101

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Sara Pilotto (S)

Department of Oncology, University of Verona Hospital Trust, Verona, Italy.

Alice Avancini (A)

Department of Oncology, University of Verona Hospital Trust, Verona, Italy.

Jessica Menis (J)

Department of Oncology, University of Verona Hospital Trust, Verona, Italy.

Isabella Sperduti (I)

Biostatistical Unit - Clinical Trials Center IRCCS Istituto Nazionale Tumori Regina Elena, U.O. di Biostatistica e Bioinformatica, Rome, Italy.

Matteo Giaj Levra (M)

Thoracic Oncology Unit, Centre Hospitalier Universitaire Grenoble Alpes (CHUGA), Grenoble, France.

Thierry Berghmans (T)

Thoracic Oncology Unit, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium.

Paolo Bironzo (P)

Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy.

Mariana Brandão (M)

Thoracic Oncology Unit, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B), Brussels, Belgium.

Dirk De Ruysscher (D)

Department of Radiation Oncology (Maastro), Maastricht University Medical Center, GROW School for Oncology, Maastricht, the Netherlands.

John Edwards (J)

Department of Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Corinne Faivre-Finn (C)

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK.

Nicolas Girard (N)

Thorax Institute Curie Montsouris, Institut Curie, 26 rue d'Ulm, Paris Cedex 05, France.

Laurent Greillier (L)

Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France.

Lizza Hendriks (L)

Department of Pulmonary Diseases, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands.

Sylvie Lantuejoul (S)

Centre Léon Bérard Unicancer, Lyon, France, Université Grenoble Alpes, Grenoble, France.

Murielle Mauer (M)

Statistics Department, EORTC Headquarters, Brussels, Belgium.

Silvia Novello (S)

Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy.

Mary O'Brien (M)

Royal Marsden Hospital, Sutton, Surrey, England.

Martin Reck (M)

Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.

Noemi Reguart (N)

Thoracic Oncology Unit, Hospital Clinic Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Jordi Remon (J)

Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, 08023 Barcelona, Spain.

Jan von der Thüsen (J)

Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands.

Anne-Marie C Dingemans (AC)

Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Benjamin Besse (B)

Faculty of Medicine, University Paris-Saclay, F-94276 Le Kremlin Bicêtre, France; Cancer Medicine Department, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.

Michele Milella (M)

Department of Oncology, University of Verona Hospital Trust, Verona, Italy. Electronic address: michele.milella@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH